Charles River fewer steps more sustainable endotoxin testing Get Started

« Previous article
FDA Issue Warning to...
Next article »

25th November 2019  Product update: rapidmicrobiology staff writer

U.S. Patent Covers Gram-Positive and Gram-Negative Sepsis-Causing Bacteria - Looking for Partners

Immunexpress has been granted Patent No. U.S. 10,364,474 B2, which covers single nucleotide polymorphisms (SNPs) in the ribosomal DNA of bacteria and fungi. Immunexpress plans to use the SNPs to identify and classify sepsis microbes in clinical patient samples.

Immunexpress' technology, SeptID™, can identify sepsis-causing bacteria as Gram-positive, Gram-negative or mixed. SeptID™ can accurately determine Gram stain status from a whole blood sample containing a microbe from a sepsis patient in approximately one hour.

Rolland D. Carlson, Ph.D., Chief Executive Officer of Immunexpress, said, "Our technology lends itself to rapid test development. It is currently formatted for an RT-qPCR machine but is not restricted to a particular technology. Our SeptID™ technology could transform the way clinicians recommend antibiotics for sepsis patients, and we are seeking strategic partners to help us achieve this goal."



Date Published: 25th November 2019

Source article link: View

Note: This content has been edited by a rapidmicrobiology staff writer for style and content.

View full company details

« Previous article
FDA Issue Warning to Pharma